The effects of ibuprofen and the neurokinin-1 receptor antagonist GR205171A on Fos expression in the ferret trigeminal nucleus following tooth pulp stimulation

European Journal of Pain

Volumn 12, Issue 3, 2008, Pages 385-394

  Worsley, Matthew A ^a   Clayton, Nick M ^b   Bountra, Chas ^b   Boissonade, Fiona M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fos; Ibuprofen; Neurokinin 1 receptor; Tooth pulp; Trigeminal nucleus

Indexed keywords

IBUPROFEN; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEIN FOS; VOFOPITANT;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENTAL CARIES; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; FERRET; JAW OPENING REFLEX; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULPITIS; SKELETAL MUSCLE; TOOTH PAIN; TOOTH PULP; TRIGEMINAL NUCLEUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CUSPID; CYCLOOXYGENASE INHIBITORS; DENTAL PULP; DRUG EVALUATION, PRECLINICAL; ELECTRIC STIMULATION; FERRETS; GENE EXPRESSION REGULATION; GENES, FOS; IBUPROFEN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-FOS; PULPITIS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TRIGEMINAL NEURALGIA; TRIGEMINAL NUCLEI;

EID: 39049167740     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2007.07.010     Document Type: Article

References (60)

1. Abbadie C., Trafton J., Liu H., Mantyh P.W., and Basbaum A.I. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci 17 (1997) 8049-8060
2. Allen B.J., Rogers S.D., Ghilardi J.R., Menning P.M., Kuskowski M.A., Basbaum A.I., et al. Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci 17 (1997) 5921-5927
3. Beaver W.T. Review of the analgesic efficacy of ibuprofen. Int J Clin Pract Suppl (2003) 13-17
4. Beiche F., Scheuerer S., Brune K., Geisslinger G., and Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390 (1996) 165-169
5. Binder W., Scott C., and Walker J.S. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci 11 (1999) 2065-2072
6. Brown J.L., Liu H., Maggio J.E., Vigna S.R., Mantyh P.W., and Basbaum A.I. Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol 356 (1995) 327-344
7. Cadden S.W., Lisney S.J., and Matthews B. Thresholds to electrical stimulation of nerves in cat canine tooth-pulp with A beta-, A delta- and C-fibre conduction velocities. Brain Res 261 (1983) 31-41
8. Clayton N.M., Oakley I., Thompson S.A.W., Sargent B., and Bountra C. Validation of the dual channel weight average as an instrument of the measurement of clinically relevant pain. Br J Pharmacol 120 Proc Suppl (1997) 219P
9. Coggeshall R.E. Fos, nociception and the dorsal horn. Prog Neurobiol 77 (2005) 299-352
10. Cumberbatch M.J., Carlson E., Wyatt A., Boyce S., Hill R.G., and Rupniak N.M. Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats. Neuropharmacology 37 (1998) 1535-1543
11. Dionne R. Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen. Int J Clin Pract Suppl (2003) 18-22
12. Dionne R.A., Max M.B., Gordon S.M., Parada S., Sang C., Gracely R.H., et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 64 (1998) 562-568
13. Duggan A.W., Hendry I.A., Morton C.R., Hutchison W.D., and Zhao Z.Q. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res 451 (1988) 261-273
14. Fukuda H., Koga T., Furukawa N., Nakamura E., and Shiroshita Y. The tachykinin NK1 receptor antagonist GR205171 prevents vagal stimulation-induced retching but not neuronal transmission from emetic vagal afferents to solitary nucleus neurons in dogs. Brain Res 802 (1998) 221-231
15. Fukuda H., Koga T., Furukawa N., Nakamura E., and Shiroshita Y. The tachykinin NK1 receptor antagonist GR205171 abolishes the retching activity of neurons comprising the central pattern generator for vomiting in dogs. Neurosci Res 33 (1999) 25-32
16. Gardner C.J., Armour D.R., Beattie D.T., Gale J.D., Hawcock A.B., Kilpatrick G.J., et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65 (1996) 45-53
17. Garry M.G., and Hargreaves K.M. Enhanced release of immunoreactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation. Brain Res 582 (1992) 139-142
18. Goadsby P.J., Hoskin K.L., and Knight Y.E. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 86 (1998) 337-343
19. Goldstein D.J., Wang O., Saper J.R., Stoltz R., Silberstein S.D., and Mathew N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17 (1997) 785-790
20. Goldstein D.J., Wang O., Todd L.E., Gitter B.D., DeBrota D.J., and Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 67 (2000) 419-426
21. Goldstein D.J., Offen W.W., Klein E.G., Phebus L.A., Hipskind P., Johnson K.W., et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21 (2001) 102-106
22. Gooch CL. The emetic response to cisplatin in the ferret: immunohistochemical and gastrointestinal studies. PhD thesis. University of Sheffield, UK; 2003.
23. Hargreaves K.M., Swift J.Q., Roszkowski M.T., Bowles W., Garry M.G., and Jackson D.L. Pharmacology of peripheral neuropeptide and inflammatory mediator release. Oral Surg Oral Med Oral Pathol 78 (1994) 503-510
24. Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans?. Trends Pharmacol Sci 21 (2000) 244-246
25. Huber M.A., and Terezhalmy G.T. The use of COX-2 inhibitors for acute dental pain: a second look. J Am Dent Assoc 137 (2006) 480-487
26. Ibuki T., Matsumura K., Yamazaki Y., Nozaki T., Tanaka Y., and Kobayashi S. Cyclooxygenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia. J Neurochem 86 (2003) 318-328
27. Jones C.K., Peters S.C., and Shannon H.E. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. Eur J Pain 11 (2007) 208-215
28. Kessler W., Kirchhoff C., Reeh P.W., and Handwerker H.O. Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. Exp Brain Res 91 (1992) 467-476
29. Le Bars D., Gozariu M., and Cadden S.W. Animal models of nociception. Pharmacol Rev 53 (2001) 597-652
30. Levine J.D., Fields H.L., and Basbaum A.I. Peptides and the primary afferent nociceptor. J Neurosci 13 (1993) 2273-2286
31. Li J.L., Wang D., Kaneko T., Shigemoto R., Nomura S., and Mizuno N. The relationship between neurokinin-1 receptor and substance P in the medullary dorsal horn: a light and electron microscopic immunohistochemical study in the rat. Neurosci Res 36 (2000) 327-334
32. Littlewood N.K., Todd A.J., Spike R.C., Watt C., and Shehab S.A. The types of neuron in spinal dorsal horn which possess neurokinin-1 receptors. Neuroscience 66 (1995) 597-608
33. Lopez J.R., Dominguez-Ramirez A.M., Cook H.J., Bravo G., Diaz-Reval M.I., Deciga-Campos M., et al. Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. Eur J Pharmacol 544 (2006) 31-38
34. Ma O.-P., and Hill R.G. Neurokinin antagonists as potential agents for use in pain management. Curr Opin Invest Drug 1 (1999) 65-71
35. Mantyh P.W., DeMaster E., Malhotra A., Ghilardi J.R., Rogers S.D., Mantyh C.R., et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268 (1995) 1629-1632
36. Miranda H.F., Puig M.M., Prieto J.C., and Pinardi G. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain 121 (2006) 22-28
37. Mjor I.A., and Tronstad L. Experimentally induced pulpitis. Oral Surg Oral Med Oral Pathol 34 (1972) 102-108
38. Nichols M.L., Allen B.J., Rogers S.D., Ghilardi J.R., Honore P., Luger N.M., et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286 (1999) 1558-1561
39. Oakden E.L., and Boissonade F.M. Correlation of substance P and calcitonin gene-related peptide with trigeminal Fos expression. J Dent Res 76 (1997) 1074
40. Oakden E.L., and Boissonade F.M. Fos expression in the ferret trigeminal nuclear complex following tooth pulp stimulation. Neuroscience 84 (1998) 1197-1208
41. Olszewski J. On the anatomical and functional organization of the spinal trigeminal nucleus. J Comp Neurol 92 (1950) 401-413
42. Parepally J.M., Mandula H., and Smith Q.R. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 23 (2006) 873-881
43. Phebus L.A., Johnson K.W., Stengel P.W., Lobb K.L., Nixon J.A., and Hipskind P.A. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 60 (1997) 1553-1561
44. Rainsford K.D. Discovery, mechanisms of action and safety of ibuprofen. Int J Clin Pract Suppl (2003) 3-8
45. Reinhardt R.R., Laub J.B., Frieke J.R., Polis A.B., and Gertz B.J. Comparison of the neurokinin-1 antagonist L-754,030, to placebo, acetaminophen and ibuprofen in the dental pain model. Clin Pharmacol Ther 63 (1998) 168
46. Ren K., Iadarola M.J., and Dubner R. An isobolographic analysis of the effects of N-methyl-d-aspartate and NK1 tachykinin receptor antagonists on inflammatory hyperalgesia in the rat. Br J Pharmacol 117 (1996) 196-202
47. Rodd H.D., and Boissonade F.M. Substance P expression in human tooth pulp in relation to caries and pain experience. Eur J Oral Sci 108 (2000) 467-474
48. Rupniak N.M., Carlson E., Boyce S., Webb J.K., and Hill R.G. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 67 (1996) 189-195
49. Sabino M.A., Honore P., Rogers S.D., Mach D.B., Luger N.M., and Mantyh P.W. Tooth extraction-induced internalization of the substance P receptor in trigeminal nucleus and spinal cord neurons: imaging the neurochemistry of dental pain. Pain 95 (2002) 175-186
50. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
51. Seybold V.S., Jia Y.P., and Abrahams L.G. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain 105 (2003) 47-55
52. Shepheard S.L., Williamson D.J., Hill R.G., and Hargreaves R.J. The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 108 (1993) 11-12
53. Shepheard S.L., Williamson D.J., Williams J., Hill R.G., and Hargreaves R.J. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34 (1995) 255-261
54. Sindrup S.H., Graf A., and Sfikas N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain 10 (2006) 567-571
55. Takeda M., Tanimoto T., Nasu M., Ikeda M., Kadoi J., and Matsumoto S. Activation of NK1 receptor of trigeminal root ganglion via substance P paracrine mechanism contributes to the mechanical allodynia in the temporomandibular joint inflammation in rats. Pain 116 (2005) 375-385
56. Traub R.J. The spinal contribution of substance P to the generation and maintenance of inflammatory hyperalgesia in the rat. Pain 67 (1996) 151-161
57. Urban L.A., and Fox A.J. NK1 receptor antagonists - are they really without effect in the pain clinic?. Trends Pharmacol Sci 21 (2000) 462-464 author reply 465
58. Worsley M.A., Davies S.L., Clayton N.M., Bountra C., Loescher A.R., Robinson P.P., et al. The effect of inflammation on Fos expression in the ferret trigeminal nucleus. Eur J Oral Sci 115 (2007) 40-47
59. Yashpal K., Pitcher G.M., and Henry J.L. Noxious peripheral stimulation produces antinociception mediated via substance P and opioid mechanisms in the rat tail-flick test. Brain Res 674 (1995) 97-103
60. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110